Can Investigational Drug Benefit Lung Cancer Surgery Patients? Request More Information Trial Objective The purpose of this clinical trial is to see if it is better to receive an investigational medication or no further treatment after surgery (and possibly chemotherapy) to remove non-small cell lung cancer (NSCLC). Two-thirds of study participants will receive the investigational medication and the other third will receive a placebo that looks like the study medication but does not contain an active drug. This research is being done because there is currently no standard treatment for patients with NSCLC who have had their cancer removed by surgery (and possibly received follow-up chemotherapy). The study medication has been shown to shrink tumors in animals, but has only been studied in a few people. Enrollment New enrollment for this trial is temporarily paused Who Can Participate Adults with non-small cell lung cancer (NSCLC) that was completely removed with surgery who may or may not have received chemotherapy after surgery. Participants cannot have lung cancer that involves a standard anti-cancer treatment at their current stage. Age: 18+ Gender: Any Gender Estimated Time Commitment Up to 12 months Treatment with the investigational medication or the placebo will last for about 12 months. All participants will be seen at 4 and 12 weeks after the end of the dosing period. Follow-up visits will then occur every 12 weeks for up to two years, then every six months for one year, and annually thereafter. The visits should take about 1.5 hours each. Our researchers would like to keep track of participants’ health for the rest of their lives to see long-term effects of participating in the study. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Not Provided Travel Reimbursement: Not Available Trial Contact For more information, contact: Jami Henriksen 303.398.1233 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors NCIC Clinical Trials Group (Canadian equivalent of NIH) Principal Investigators Laurie Carr, MD + × Laurie Carr, MD Associate Professor Department of Medicine Division of Oncology, Cancer Center View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment Request More Information Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus. First Name:* Last Name:* Email Address:* Phone:*
Trial Objective The purpose of this clinical trial is to see if it is better to receive an investigational medication or no further treatment after surgery (and possibly chemotherapy) to remove non-small cell lung cancer (NSCLC). Two-thirds of study participants will receive the investigational medication and the other third will receive a placebo that looks like the study medication but does not contain an active drug. This research is being done because there is currently no standard treatment for patients with NSCLC who have had their cancer removed by surgery (and possibly received follow-up chemotherapy). The study medication has been shown to shrink tumors in animals, but has only been studied in a few people.